Louis Boon
Dr. Boon received his Ph.D. in Biochemistry at the University of Amsterdam
Dr. Boon received his Ph.D. in Biochemistry at the University of Amsterdam. He also carried out post-doctoral positions at University of Amsterdam at the Department of Anatomy and Embryology and at the Department of Clinical Epidemiology. Thereafter he was one of the founders of PanGenetics where he was responsible for project management and animal studies. Since the merger between PanGenetics and Tanox Inc. in Houston, he had the position of VP Preclinical in which he was world-wide responsible for preclinical safety assessments and animals studies for the Tanox group. Dr. Boon has performed antibody therapy for immunoinflammatory diseases both in murine and non-human primate disease models and healthy non-human primates. Thereafter Dr. Boon was one of the founders of MacroZyme BV and for 2 years Director of Preclinical R&D of MacroZyme BV, where he was responsible for a small molecule project in the metabolic field and various potential protein-based therapeutic molecules. In 2003 he was one of the founders of Bioceros BV where he currently holds a position of Chief Scientific Officer



Speakers
















































